Key result
High abdominal aortic calcification index linked to ~220% greater cardiovascular event risk in CKD.
Why the study?
Abdominal aortic calcification index has been investigated as a prognostic marker in chronic kidney disease, but its association with clinical outcomes remains uncertain.
Does a high baseline abdominal aortic calcification index predict poorer cardiovascular event-free survival and overall survival in adult patients with chronic kidney disease?
Meta-Analysis (n=1,914)
Does a high baseline abdominal aortic calcification index predict poorer cardiovascular event-free survival and overall survival in adult patients with chronic kidney disease?
Hazard Ratio: 3.2 (95% CI 2.21–4.64)
p-value: p=<0.001
A high baseline abdominal aortic calcification index is a significant imaging biomarker for predicting poorer cardiovascular event-free survival and overall survival in patients with chronic kidney disease.
Background Abdominal aortic calcification index (ACI), a quantitative computed tomography–based measure of abdominal aortic calcification burden, has been increasingly investigated as a prognostic marker in patients with chronic kidney disease (CKD). However, the association between ACI and clinical outcomes in CKD remains uncertain. This meta-analysis evaluated the association of baseline ACI with cardiovascular event-free survival (CVEFS) and overall survival (OS) in patients with CKD. Methods PubMed, Embase, Web of Science, Wanfang Data, and CNKI were searched for cohort studies evaluating the association between baseline ACI and prognosis in adult patients with CKD. Hazard ratios (HRs) comparing high versus low ACI were pooled using random-effects models accounting for the influence of potential heterogeneity. Prespecified subgroup, sensitivity, and meta-regression analyses were performed. Results Eleven cohort studies involving 1,914 patients with CKD were included. Nine studies reported CVEFS and five reported OS. Pooled analysis showed that a high ACI was associated with poorer CVEFS (HR = 3.20, 95% CI: 2.21–4.64; I 2 = 44%) and OS (HR = 2.69, 95% CI: 1.86–3.89; I 2 = 0%). The association with CVEFS remained significant across study design and renal replacement therapy subgroups. Stronger associations with CVEFS were observed in studies with a mean age < 60 years as compared to ≥ 60 years (HR = 5.46 vs. 2.27; p for subgroup difference = 0.01) and ACI cutoff values ≥ 30% compared to < 30% (HR = 8.53 vs. 2.37; p < 0.001). Meta-regression identified ACI cutoff value as the only significant study characteristic associated with the strength of the association between ACI and CVEFS (coefficient = 0.033, p = 0.02). Conclusion A high baseline ACI was associated with poorer CVEFS and OS in patients with CKD. ACI may have potential as an imaging biomarker for prognostic risk stratification in this population, although these findings should be interpreted cautiously and confirmed in future prospective studies. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420261421928.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) conducted a meta-analysis in Chronic kidney disease (n=1,914). High baseline abdominal aortic calcification index (ACI) vs. Low baseline ACI was evaluated on Cardiovascular event-free survival (CVEFS) (HR 3.20, 95% CI 2.21-4.64, p=<0.001). A high baseline abdominal aortic calcification index was significantly associated with poorer cardiovascular event-free survival (HR 3.20) in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: